Kymera Therapeutics and Sanofi Advance KT-485 into Clinical Development for Immune Diseases
Thursday, June 26, 2025
Kymera Therapeutics has announced an update regarding its partnership with Sanofi on the IRAK4 programme.
KT-485 is designed to treat immuno-inflammatory diseases where significant unmet need remains. IRAK4 plays a key role in regulating innate immunity and inflammatory signalling through IL-1 and toll-like receptors. Unlike traditional small molecule inhibitors, KT-485 works by degrading IRAK4, potentially affecting both its kinase and scaffolding functions. This mechanism may offer a more comprehensive and well-tolerated anti-inflammatory response.
Sanofi has selected KT-485 (also known as SAR447971), an oral, potent, and selective IRAK4 degrader, to move forward into clinical development. KT-485 was discovered and developed by Kymera through extensive preclinical studies. It will now be prioritised under the companies’ existing collaboration, with Phase 1 trials expected to begin in 2026. As a result of this decision, Sanofi will no longer continue development of KT-474, an earlier candidate in the same programme.
In line with this development, Sanofi has chosen to exercise its participation rights under the terms of the collaboration. Kymera has received a milestone payment of US$20 million in Q2 2025 related to KT-485’s preclinical progress. The company remains eligible for up to US$975 million in future clinical, regulatory, and commercial milestones, including a payment once KT-485 enters Phase 1 trials.
Sanofi and Kymera will continue their collaboration in this area, excluding oncology and immuno-oncology indications.
Source: kymeratx.com
